Floatz logo

DARATUMUMAB

Gammopathy, Monoclonal

Hellenic Society of Hematologymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Gammopathy, Monoclonal cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Liraglutide
University of Miami
Phase 4BB
Inno-206
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3BB
(+)-VINCRISTINE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
gsk2857916
Hellenic Society of Hematology
Phase 1/2CC

View all 11 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →